WallStreetZenWallStreetZen

NASDAQ: OPT
Opthea Ltd Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for OPT

Based on 2 analysts offering 12 month price targets for Opthea Ltd.
Min Forecast
$14.00+495.74%
Avg Forecast
$15.00+538.3%
Max Forecast
$16.00+580.85%

Should I buy or sell OPT stock?

Based on 2 analysts offering ratings for Opthea Ltd.
Buy
Strong Buy
0 analysts 0%
Buy
2 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their OPT stock forecasts and price targets.

OPT stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2023-09-13
lockedlocked$00.00+00.00%2023-08-01

1 of 1

Forecast return on equity

Is OPT forecast to generate an efficient return?

Forecast return on assets

Is OPT forecast to generate an efficient return on assets?
Company
N/A
Industry
-0.13%

OPT revenue forecast

What is OPT's revenue in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
$17.2M+4,351.37%
Avg 2 year Forecast
$17.2M+4,359.93%
Avg 3 year Forecast
$111.2M+28,761.46%
OPT's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

OPT revenue growth forecast

How is OPT forecast to perform vs Biotechnology companies and vs the US market?
Company
528.24%
Industry
34.07%
Market
7.56%
OPT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
OPT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

OPT vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
OPT$2.35$15.00+538.30%Buy
ANNX$2.57$19.67+665.25%Strong Buy
VTYX$2.30$34.14+1,384.48%Buy
STRO$2.28$14.86+551.62%Strong Buy
KOD$2.66$4.00+50.38%Sell
View Top Biotech Stocks

Opthea Stock Forecast FAQ

Is Opthea Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: OPT) stock is to Buy OPT stock.

Out of 2 analysts, 0 (0%) are recommending OPT as a Strong Buy, 2 (100%) are recommending OPT as a Buy, 0 (0%) are recommending OPT as a Hold, 0 (0%) are recommending OPT as a Sell, and 0 (0%) are recommending OPT as a Strong Sell.

If you're new to stock investing, here's how to buy Opthea stock.

What is OPT's revenue growth forecast for 2024-2026?

(NASDAQ: OPT) Opthea's forecast annual revenue growth rate of 528.24% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.07%, and it is also forecast to beat the US market's average forecast revenue growth rate of 7.56%.

Opthea's revenue in 2023 is $385,275.On average, 3 Wall Street analysts forecast OPT's revenue for 2024 to be $8,011,783,264, with the lowest OPT revenue forecast at $46,715,937, and the highest OPT revenue forecast at $23,357,968,700. On average, 3 Wall Street analysts forecast OPT's revenue for 2025 to be $8,027,199,523, with the lowest OPT revenue forecast at $46,715,937, and the highest OPT revenue forecast at $23,357,968,700.

In 2026, OPT is forecast to generate $51,946,253,751 in revenue, with the lowest revenue forecast at $11,678,984,350 and the highest revenue forecast at $115,617,273,471.

What is OPT's forecast return on assets (ROA) for 2024-2026?

(NASDAQ: OPT) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of -0.13%.

What is OPT's Price Target?

According to 2 Wall Street analysts that have issued a 1 year OPT price target, the average OPT price target is $15.00, with the highest OPT stock price forecast at $16.00 and the lowest OPT stock price forecast at $14.00.

On average, Wall Street analysts predict that Opthea's share price could reach $15.00 by Sep 13, 2024. The average Opthea stock price prediction forecasts a potential upside of 538.3% from the current OPT share price of $2.35.

What is OPT's forecast return on equity (ROE) for 2024-2026?

(NASDAQ: OPT) forecast ROE is N/A, which is considered weak.
©2023 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.